Can reducing peaks prevent type 2 diabetes: Implication from recent diabetes prevention trials

International Journal of Clinical Practice, Supplement

Volumn , Issue 129, 2002, Pages 33-39

  Haffner, Steven M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

BODY MASS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; ETHNOLOGY; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; ISCHEMIC HEART DISEASE; LIFESTYLE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; WEIGHT REDUCTION; CARDIOVASCULAR DISEASE; PHYSIOLOGY; REVIEW;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; LIFE STYLE; METFORMIN; POSTPRANDIAL PERIOD; RANDOMIZED CONTROLLED TRIALS; SMOKING CESSATION; WEIGHT LOSS;

EID: 0036021730     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates and projections
2. Epidemiology of type 2 diabetes
3. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the clinical onset of diabetes?
4. Diabetes and decline in heart disease mortality in the US adults
5. Productivity and medical costs of diabetes in a large employer population
6. Identification of diabetes patients using claims data: An economic analysis
7. Impaired glucose tolerance and impaired fasting glucose
8. Predictors of progression from impaired glucose tolerance to NIDDM: An analysis of six prospective studies
9. The natural history of impaired glucose tolerance in Pima Indians
10. An integrated view of β-cell dysfunction in type-II diabetes
11. Glucose toxicity
12. Importance of postprandial glucose control
13. Mechanisms of tissue damage in the postprandial state
14. Rationale for prevention and treatment of postprandial glucose toxicity
15. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes
16. The importance of hyperglycaemia in the nonfasting state to the development of cardiovascular disease
17. Postprandial state and the risk of atherosclerosis
18. Peripheral artery disease in relation to glycemic level in elderly Caucasian population: The Hoon study
19. Nonfasting serum glucose and the risk of fatal stroke in diabetic and nondiabetic subjects. 18-year follow-up of the Oslo Study
20. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
21. Vascular complications in long-term South Indian NIDDM of over 25 years of duration
22. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
23. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects
24. Effect of physical training on insulin action in obesity
25. Pathophysiology and pharmacologic treatment of insulin resistance
26. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Quing IGT and Diabetes Study
27. Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance
28. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial
29. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
30. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Implications for preventing coronary heart disease during prediabetic state
31. Asymptomatic hyperglycaemia is associated with increased intima media thickness of the carotid artery
32. Vascular abnormalities in the prediabetic state
33. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up